147 related articles for article (PubMed ID: 21450822)
1. Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo.
Cary ZD; Willingham MC; Lyles DS
J Virol; 2011 Jun; 85(12):5708-17. PubMed ID: 21450822
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
[TBL] [Abstract][Full Text] [Related]
3. Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.
Felt SA; Moerdyk-Schauwecker MJ; Grdzelishvili VZ
Virology; 2015 Jan; 474():163-73. PubMed ID: 25463614
[TBL] [Abstract][Full Text] [Related]
4. Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum.
Pipperger L; Koske I; Wild N; Müllauer B; Krenn D; Stoiber H; Wollmann G; Kimpel J; von Laer D; Bánki Z
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243134
[TBL] [Abstract][Full Text] [Related]
5. Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors.
Gao Y; Bergman I
J Virol; 2023 Jun; 97(6):e0037223. PubMed ID: 37199666
[TBL] [Abstract][Full Text] [Related]
6. Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
Nelson A; McMullen N; Gebremeskel S; De Antueno R; Mackenzie D; Duncan R; Johnston B
Breast Cancer Res; 2024 May; 26(1):78. PubMed ID: 38750591
[TBL] [Abstract][Full Text] [Related]
7. Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation.
Leveille S; Goulet ML; Lichty BD; Hiscott J
J Virol; 2011 Dec; 85(23):12160-9. PubMed ID: 21917977
[TBL] [Abstract][Full Text] [Related]
8. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.
Obuchi M; Fernandez M; Barber GN
J Virol; 2003 Aug; 77(16):8843-56. PubMed ID: 12885903
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy.
Kottke T; Tonne J; Evgin L; Driscoll CB; van Vloten J; Jennings VA; Huff AL; Zell B; Thompson JM; Wongthida P; Pulido J; Schuelke MR; Samson A; Selby P; Ilett E; McNiven M; Roberts LR; Borad MJ; Pandha H; Harrington K; Melcher A; Vile RG
Nat Commun; 2021 Mar; 12(1):1930. PubMed ID: 33772027
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Therapy of Solid Tumors by Modified Vesicular Stomatitis Virus.
Gao Y
DNA Cell Biol; 2024 Feb; 43(2):57-60. PubMed ID: 38079267
[TBL] [Abstract][Full Text] [Related]
11. Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity.
Olagnier D; Lababidi RR; Hadj SB; Sze A; Liu Y; Naidu SD; Ferrari M; Jiang Y; Chiang C; Beljanski V; Goulet ML; Knatko EV; Dinkova-Kostova AT; Hiscott J; Lin R
Mol Ther; 2017 Aug; 25(8):1900-1916. PubMed ID: 28527723
[TBL] [Abstract][Full Text] [Related]
12. Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms.
Kim DS; Dastidar H; Zhang C; Zemp FJ; Lau K; Ernst M; Rakic A; Sikdar S; Rajwani J; Naumenko V; Balce DR; Ewanchuk BW; Tailor P; Yates RM; Jenne C; Gafuik C; Mahoney DJ
Nat Commun; 2017 Aug; 8(1):344. PubMed ID: 28839138
[TBL] [Abstract][Full Text] [Related]
13. NEBL and AKT1 maybe new targets to eliminate the colorectal cancer cells resistance to oncolytic effect of vesicular stomatitis virus M-protein.
Mamizadeh Z; Kalani MR; Parsania M; Soltan Dallal MM; Moradi A
Mol Ther Oncolytics; 2021 Dec; 23():593-601. PubMed ID: 34977336
[TBL] [Abstract][Full Text] [Related]
14. Identification of two additional translation products from the matrix (M) gene that contribute to vesicular stomatitis virus cytopathology.
Jayakar HR; Whitt MA
J Virol; 2002 Aug; 76(16):8011-8. PubMed ID: 12134006
[TBL] [Abstract][Full Text] [Related]
15. Synergistic VSV Virotherapy and Carbon Nanotube Photothermal Therapy for Osteosarcoma in Murine Models.
Sakuda T; Oda A; Furuta T; Johan MP; Sakaguchi T; Adachi N
Anticancer Res; 2024 Jan; 44(1):99-105. PubMed ID: 38159977
[TBL] [Abstract][Full Text] [Related]
16. Repurposing of Zika virus live-attenuated vaccine (ZIKV-LAV) strains as oncolytic viruses targeting human glioblastoma multiforme cells.
Victorio CBL; Novera W; Ganasarajah A; Ong J; Thomas M; Wu J; Toh HSY; Sun AX; Ooi EE; Chacko AM
J Transl Med; 2024 Feb; 22(1):126. PubMed ID: 38308299
[TBL] [Abstract][Full Text] [Related]
17. Cre-Dependent Anterograde Transsynaptic Labeling and Functional Imaging in Zebrafish Using VSV With Reduced Cytotoxicity.
Kler S; Ma M; Narayan S; Ahrens MB; Pan YA
Front Neuroanat; 2021; 15():758350. PubMed ID: 34720892
[TBL] [Abstract][Full Text] [Related]
18. Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV.
Yarde DN; Naik S; Nace RA; Peng KW; Federspiel MJ; Russell SJ
Cancer Gene Ther; 2013 Nov; 20(11):616-21. PubMed ID: 24176894
[TBL] [Abstract][Full Text] [Related]
19. Induction of cytopathogenicity in human glioblastoma cells by chikungunya virus.
Abraham R; Mudaliar P; Padmanabhan A; Sreekumar E
PLoS One; 2013; 8(9):e75854. PubMed ID: 24086645
[TBL] [Abstract][Full Text] [Related]
20. Differential Susceptibility of Ex Vivo Primary Glioblastoma Tumors to Oncolytic Effect of Modified Zika Virus.
Garcia G; Chakravarty N; Paiola S; Urena E; Gyani P; Tse C; French SW; Danielpour M; Breunig JJ; Nathanson DA; Arumugaswami V
Cells; 2023 Sep; 12(19):. PubMed ID: 37830597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
